The COVAIL study was a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection in comparison to a prototype mRNA. This study enrolled 706 participants across 22 US sites including the GW VRU. The results adds to the evidence that matching COVID-19 vaccines to the currently circulating strains should provide better protection.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: